Abstract A065: Mutant GNAS drives cAMP/PDE/AMP–pAMPK signaling and therapeutic synergy with combined CDK4/6 and RAS inhibition in mucinous pancreatic neoplasia
Intraductal Papillary Mucinous Neoplasm (IPMN) are pre-malignant lesions of the pancreas with frequent co-mutations in KRAS and GNAS oncogenes. We recently reported pancreatic neoplasia from both primary and metastatic disease with KRAS/GNAS mutations are sensitive to single agent treatment with the FDA approved cell...